OBJECTIVES: To investigate serum levels of glial fibrillary acidic protein (GFAP) and S-100B in patients with newly diagnosed high-grade gliomas. MATERIALS AND METHODS: GFAP and S-100B were measured by enzyme-linked immunosorbent assay techniques in preoperative serum from 31 patients with high-grade gliomas. A database with clinical, radiological and histological variables was created for statistical analyses. RESULTS: Mean serum levels of 239 ng/l (range 30-1210 ng/l) for GFAP and 58.3 ng/l (range 22-128 ng/l) for S-100B were found. Of the 31 patients, 16 had elevated levels of GFAP while only two showed increased S-100B concentrations. Tumour size was the only variable significantly associated with serum levels of GFAP (P < 0.0001) with a linear correlation coefficient of 0.67. CONCLUSIONS: Serum levels of GFAP demonstrated a linear correlation to tumour volume in patients with high-grade gliomas. GFAP seems to be a more reliable biomarker in patients with high-grade gliomas than the commercially available S-100B.
OBJECTIVES: To investigate serum levels of glial fibrillary acidic protein (GFAP) and S-100B in patients with newly diagnosed high-grade gliomas. MATERIALS AND METHODS:GFAP and S-100B were measured by enzyme-linked immunosorbent assay techniques in preoperative serum from 31 patients with high-grade gliomas. A database with clinical, radiological and histological variables was created for statistical analyses. RESULTS: Mean serum levels of 239 ng/l (range 30-1210 ng/l) for GFAP and 58.3 ng/l (range 22-128 ng/l) for S-100B were found. Of the 31 patients, 16 had elevated levels of GFAP while only two showed increased S-100B concentrations. Tumour size was the only variable significantly associated with serum levels of GFAP (P < 0.0001) with a linear correlation coefficient of 0.67. CONCLUSIONS: Serum levels of GFAP demonstrated a linear correlation to tumour volume in patients with high-grade gliomas. GFAP seems to be a more reliable biomarker in patients with high-grade gliomas than the commercially available S-100B.
Authors: Peter Baumgarten; Johanna Quick-Weller; Florian Gessler; Marlies Wagner; Julia Tichy; Marie-Therese Forster; Christian Foerch; Volker Seifert; Michel Mittelbronn; Christian Senft Journal: J Neurooncol Date: 2018-05-24 Impact factor: 4.130
Authors: Aida Kiviniemi; Maria Gardberg; Janek Frantzén; Riitta Parkkola; Ville Vuorinen; Marko Pesola; Heikki Minn Journal: J Neurooncol Date: 2015-06-02 Impact factor: 4.130
Authors: Johan M Kros; Dana M Mustafa; Lennard J M Dekker; Peter A E Sillevis Smitt; Theo M Luider; Ping-Pin Zheng Journal: Neuro Oncol Date: 2014-09-24 Impact factor: 12.300
Authors: Julia Tichy; Sabrina Spechtmeyer; Michel Mittelbronn; Elke Hattingen; Johannes Rieger; Christian Senft; Christian Foerch Journal: J Neurooncol Date: 2015-10-30 Impact factor: 4.130
Authors: Ayseguel Ilhan-Mutlu; Anna S Berghoff; Julia Furtner; Karin Dieckmann; Irene Slavc; Thomas Czech; Christine Marosi; Ludwig Wagner; Matthias Preusser Journal: J Neurooncol Date: 2013-04-29 Impact factor: 4.130